Amniotics AB Stock

Equities

AMNI

SE0015961016

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 09:25:49 2024-04-26 am EDT 5-day change 1st Jan Change
0.0038 SEK 0.00% Intraday chart for Amniotics AB 0.00% -57.78%
Sales 2023 - Sales 2024 * - Capitalization 10.39M 114M
Net income 2023 -30M -328M Net income 2024 * -23M -252M EV / Sales 2023 -
Net cash position 2023 * - 0 Net cash position 2024 * 7.9 86.43 EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 6
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.64%
More Fundamentals * Assessed data
Dynamic Chart
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million. CI
Amniotics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Amniotics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Amniotics Secures Orphan Designation for Lung Injury Therapy from European Commission MT
Amniotics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Amniotics AB Gets Renewed GMP Certification for Medicinal Products Manufacturing Site MT
European Medicines Agency Panel Backs Amniotics AB’s PulmoStem for Orphan Designation MT
Amniotics AB Receives Positive Opinion on Orphan Designation for PulmoStem from the European Medicines Agency for the Treatment of Primary Graft Dysfunction Following Lung Transplantation CI
Amniotics AB Receives Final Clinical Study Report for the Phase Ib Clinical Trial CI
Certain Ordinary Shares of Amniotics AB are subject to a Lock-Up Agreement Ending on 9-SEP-2023. CI
Amniotics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Amniotics AB Announces Delay in Publication of Earnings Result for the Second Quarter of 2023 CI
Amniotics AB Announces Positive Interim Results with CogniStem CI
Amniotics AB Receives Positive Topline Results from Clinical Phase Ib Study with PulmoStem CI
Amniotics AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
3 months-52.50%
6 months-81.00%
Current year-57.78%
More quotes
1 week
0.00
Extreme 0.0036
0.00
1 month
0.00
Extreme 0.0036
0.00
Current year
0.00
Extreme 0.0022
0.01
1 year
0.00
Extreme 0.0022
0.15
3 years
0.00
Extreme 0.0022
23.00
5 years
0.00
Extreme 0.0022
23.00
10 years
0.00
Extreme 0.0022
23.00
More quotes
Managers TitleAgeSince
Founder 51 15-08-31
Director of Finance/CFO 53 23-05-01
Chief Tech/Sci/R&D Officer 49 -
Members of the board TitleAgeSince
Chairman 69 21-04-14
Director/Board Member 61 21-04-14
Director/Board Member 66 21-04-14
More insiders
Date Price Change Volume
24-04-26 0.0038 0.00% 1,787,282
24-04-25 0.0038 -2.56% 5,848,188
24-04-24 0.0039 0.00% 12,056,260
24-04-23 0.0039 +5.41% 4,675,404
24-04-22 0.0037 -2.63% 2,579,680

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 09:25 am EDT

More quotes
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
More about the company

Annual profits - Rate of surprise